CD274 and neoplasm: Biomarkers such as the tumor mutation burden (TMB), PD-L1 expression, deficient mismatch repair gene expression or microsatellite instability-high (dMMR/MSI-H), tumor-infiltrating lymphocytes, and gene expression programming (TILs/GEP) are reported to be able to predict ICI efficacy [23–27].